摘要
目的探讨前列腺素E合成酶(mPGES-1)和环氧化酶(COX-2)在肺癌组织中的表达及生物学意义。方法采用RT—PCR检测肺癌及癌旁组织中mPGES-1、COX-2mRNA的表达,同时采用免疫组织化学S—P法检测相应标本中mPGES-1和COX-2蛋白的表达。结果肺癌组织中mPGES-1和COX-2mRNA的表达量均明显高于癌旁组织(均P〈0.05);mPGES-1蛋白阳性表达率在肺癌组织中为66.7%(40/60)明显高于相应癌旁组织中的10.0%(6/60)(x2=20.38,P〈0.01);COX-2蛋白的阳性表达率在肺癌组织中为73.3%(44/60)明显高于在相应的癌旁组织中的13.3%(8/60)(X2=21.99,P〈0.01)。肺癌组织中mPGES-1和COX-2蛋白的阳性表达率与肿瘤大小、组织类型无关(均P〉0.05),而与淋巴结转移、TNM分期、分化程度等有关(均P〈0.05)。结论mPGES-1和COX-2的高表达可能在肺癌的发生发展中起着重要作用,可能为肺癌的早期诊断和开发肺癌的靶向治疗提供一定的临床依据。
Objective To explore the expression and biological significance of microsomal prostaglan din E synthase-1 ( mPGES-1 ) and cyclooxyenase-2 (COX-2) in lung cancer. Methods The expressions of mPGES-1 and COX-2 mRNA in cancerous tissue and tumor-adjacent tissue were detected by RT-PCR,while the immunohistochemi- cal S-P method was used to evaluate the expression of mPGES-1 and COX-2 proteins in the corresponding tissues. Results The mRNA level of COX-2 and mPGES-1 significantly increased(P 〈 0.05) in lung cancer group as com- pared with those in the tumor-adjacent tissue. The positive expression rate of mPGES-1 in cancerous tissue and tumor- adjacent tissue were 66.7% (40/60) and 10.0% (6/60) respectively. The positive expression rate of COX-2 protein in cancerous tissue and tumor-adjacent tissue were 73.3% (44/60)and 13.3% (8/60) ,respectively. The positive expression rate of COX-2 was significantly higher in lung cancer than in tumor-adjacent tissue ( X2 = 21.99, P 〈 0.01 ). The positive expression rate of mPGES-1 and COX-2 protein in lung cancer was independent of size of tumor and histological type ( P 〉 0.05 ), but correlated with histological grade, lymph node metastasis and TNM staging. ( P 〈 0. 05 ). Conclusion It suggested that the expression of mPGES-1 and COX-2 in lung cancer may play an important role in the process of carcinogenesis, and may provide a clinical basis for the early diagnosis and targeted therapy of lung cancer.
出处
《中国基层医药》
CAS
2012年第6期825-827,共3页
Chinese Journal of Primary Medicine and Pharmacy
基金
内蒙古自治区自然科学基金资助项目(2009MS1125)